Abstract
The alpha emitters 225Ac and 213Bi are promising therapeutic radionuclides for application in targeted alpha therapy of cancer and infectious diseases. Both alpha emitters are available with high specific activity from established radionuclide generators. Their favourable chemical and physical properties have led to the conduction of a large number of preclinical studies and several clinical trials, demonstrating the feasibility, safety and therapeutic efficacy of targeted alpha therapy with 225Ac and 213Bi. This review describes methods for the production of 225Ac and 213Bi and gives an overview of 225Ac/213Bi radionuclide generator systems. Selected preclinical studies are highlighted and the current clinical experience with 225Ac and 213Bi is summarized.
Keywords: Targeted alpha therapy, Alpha emitter, Actinium-225, Bismuth-213, Preclinical, Clinical studies, DOTA-biotin, xenografts, DOTATOC, AMBA
Current Radiopharmaceuticals
Title:Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Volume: 5 Issue: 3
Author(s): Alfred Morgenstern, Frank Bruchertseifer and Christos Apostolidis
Affiliation:
Keywords: Targeted alpha therapy, Alpha emitter, Actinium-225, Bismuth-213, Preclinical, Clinical studies, DOTA-biotin, xenografts, DOTATOC, AMBA
Abstract: The alpha emitters 225Ac and 213Bi are promising therapeutic radionuclides for application in targeted alpha therapy of cancer and infectious diseases. Both alpha emitters are available with high specific activity from established radionuclide generators. Their favourable chemical and physical properties have led to the conduction of a large number of preclinical studies and several clinical trials, demonstrating the feasibility, safety and therapeutic efficacy of targeted alpha therapy with 225Ac and 213Bi. This review describes methods for the production of 225Ac and 213Bi and gives an overview of 225Ac/213Bi radionuclide generator systems. Selected preclinical studies are highlighted and the current clinical experience with 225Ac and 213Bi is summarized.
Export Options
About this article
Cite this article as:
Morgenstern Alfred, Bruchertseifer Frank and Apostolidis Christos, Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes, Current Radiopharmaceuticals 2012; 5 (3) . https://dx.doi.org/10.2174/1874471011205030221
DOI https://dx.doi.org/10.2174/1874471011205030221 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Editorial (Thematic Issue: New Therapeutic Approaches for the Treatment of Glioblastoma)
Current Cancer Drug Targets Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids
Current Topics in Medicinal Chemistry Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science DNA-Based Methods to Prepare Helper Virus-Free Herpes Amplicon Vectors and Versatile Design of Amplicon Vector Plasmids
Current Gene Therapy The Use of PET for Radiotherapy
Current Medical Imaging Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Targeting the Central Nervous System with Herpes Simplex Virus / Sleeping Beauty Hybrid Amplicon Vectors
Current Gene Therapy Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets